Variants in GLP1R, GIPR, FTO, and MC4R genes correlate with differential GLP-1 responsiveness, though genetics alone does not determine outcome
Skin whitening and brightening are not gendered concerns
10.2337/diabetes.50.3.609 191 WaughN.CumminsE.RoyleP.ClarC.MarienM.RichterB.et al (2010)
The team has now treated about a third of the 60 patients and say that early results are promising for psilocybin
Initially developed for type 2 diabetes, GLP-1RAs have demonstrated robust weight loss in randomized controlled trials and real-world settings, leading to their repositioning as cornerstone obesity treatments ( Human metabolic studies consistently show that reductions in energy intake account for most of the weight loss observed during GLP-1RA therapy, whereas increases in resting energy expenditure are modest or absent ( Beyond total weight loss, the quality of weight loss has become an increasingly important clinical concern
Some of the most common NCDs driven by a high BMI are diabetes, coronary heart disease, stroke, and even cancer